Pfizer and Sangamo dosed the first patient in their Phase III AFFINE study of giroctocogene fitelparvovec, and with the trial’s endpoint follow-up at 12 months, it could put the partners very close to the timing...

EMA's CHMP recommended conditional approval of Crysvita burosumab (KRN23, UX023) from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children ages one and up and...

EMA's CHMP recommended approval of a host of therapies, including Alofisel darvadstrocel (Cx601) to treat Crohn's disease, Ozempic semaglutide (NN9924, OG217SC) to treat Type II diabetes, Herzuma biosimilar trastuzumab to treat breast and gastric cancer...